Value of hsCRP and Alb in Evaluating the Prognosis of Patients with Systemic Lupus Erythematosus.
- Author:
Tian-Ling ZHANG
1
;
Jia-Feng NIU
1
;
Ji-Tao LIU
1
;
Tian-Yu HU
1
;
Qing LI
2
Author Information
- Publication Type:Journal Article
- From: Journal of Experimental Hematology 2017;25(4):1218-1222
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the value of hsCRP and Alb in evaluating the prognosis of patients with systemic lupus erythematosus (SLE).
METHODS126 SLE patients from January 2011 to January 2016 were enrolled in this study, and their clinical data were collected, including SLEDAI, hsCRP and Alb and complications. The correlation between hsCRP/Alb ratio and SLEDAI after treatment was analyzed. All patients were followed up after discharge, and the prognosis-related factors were analyzed.
RESULTSAfter treatment, hsCRP/Alb ratio of patients with SLEDAI 10-14 score was significantly higher than that of 5-9 and 0-4 score(P<0.05). hsCRP/Alb ratio was positively correlated with infection (r=0.574), renal damage (r=0.499) and cardiac injury (r=0.516) (P<0.05), while it demonstrated no correlation with blood system damage, CNS damage and lung injury(P>0.05). after treatment SLEDAI ≥10 score, hsCRP/Alb≥0.05 mg/g and complications significantly correlated with prognosis of patients(P<0.05).
CONCLUSIONhsCRP/Alb correlates with the prognosis of patients with SLE at a certam level.
